Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[New systemic therapies in oncology].
Zaman K, Ketterer N, Vulliémoz D, Stupp R, Leyvraz S. Zaman K, et al. Rev Med Suisse. 2005 May 18;1(20):1361-2, 1364-5. Rev Med Suisse. 2005. PMID: 15991629 Review. French.
Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors.
Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC, Fagiani E, Zaman K, Stupp R, Shibuya M, Delaloye JF, Christofori G, Ruegg C. Laurent J, et al. Among authors: zaman k. Cancer Res. 2011 Jun 1;71(11):3781-91. doi: 10.1158/0008-5472.CAN-10-3684. Epub 2011 Apr 20. Cancer Res. 2011. PMID: 21507936
[Present chemoprevention and future vision].
Filges I, Zaman K, Michielin O, Vulliémoz D, Perey L, Stupp R. Filges I, et al. Among authors: zaman k. Rev Med Suisse. 2005 May 18;1(20):1343-6, 1349. Rev Med Suisse. 2005. PMID: 15991626 Review. French.
Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.
Guex N, Crespo I, Bron S, Ifticene-Treboux A, Faes-Van't Hull E, Kharoubi S, Liechti R, Werffeli P, Ibberson M, Majo F, Nicolas M, Laurent J, Garg A, Zaman K, Lehr HA, Stevenson BJ, Rüegg C, Coukos G, Delaloye JF, Xenarios I, Doucey MA. Guex N, et al. Among authors: zaman k. PLoS Comput Biol. 2015 Mar 13;11(3):e1004050. doi: 10.1371/journal.pcbi.1004050. eCollection 2015 Mar. PLoS Comput Biol. 2015. PMID: 25768678 Free PMC article.
Elevated liver function tests in a patient with breast cancer.
Neftel C, Zaman K, Chtioui H, Moradpour D, Sempoux C, Fraga M. Neftel C, et al. Among authors: zaman k. J Hepatol. 2023 Sep;79(3):e109-e111. doi: 10.1016/j.jhep.2023.07.002. J Hepatol. 2023. PMID: 37599061 Free article. No abstract available.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: zaman k. BMC Cancer. 2016 Oct 10;16(1):780. doi: 10.1186/s12885-016-2823-y. BMC Cancer. 2016. PMID: 27724870 Free PMC article. Clinical Trial.
749 results